SCHEMBL26906510

SCHEMBL26906510

CN1CCN(C2CCN(c3ccc(Nc4ncc(Br)c(Nc5cc6c(cc5CS(=O)(=O)NC=O)CCO6)n4)c(Cl)c3)CC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 13/20 0.49
▸ INSR P06213 11/20 0.49
▸ IGF1R P08069 10/20 0.49
▸ EGFR P00533 8/20 0.48
▸ MET P08581 2/20 0.48
▸ FGFR1 P11362 2/20 0.46
▸ FGFR2 P21802 2/20 0.46
▸ FGFR4 P22455 2/20 0.46
▸ FGFR3 P22607 2/20 0.46
▸ BMPR1B O00238 1/20 0.46
▸ PLK4 O00444 1/20 0.46
▸ STK25 O00506 1/20 0.46
▸ RIOK3 O14730 1/20 0.46
▸ CHEK1 O14757 1/20 0.46
▸ CASK O14936 1/20 0.46
▸ AURKA O14965 1/20 0.46
▸ GAK O14976 1/20 0.46
▸ DCLK1 O15075 1/20 0.46
▸ MUSK O15146 1/20 0.46
▸ EPHB6 O15197 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27116840 0.91 EGFR (0.52) ALKINSRIGF1REGFRMET
SCHEMBL29904683 0.91 EGFR (0.52) ALKINSRIGF1REGFRMET
SCHEMBL29114963 0.86 EGFR (0.59) ALKINSRIGF1REGFRMET
SCHEMBL30860744 0.85 EGFR (0.60) ALKINSRIGF1REGFRMET
SCHEMBL26906761 0.81 EGFR (0.66) ALKINSRIGF1REGFRMET
SCHEMBL30860285 0.79 EGFR (0.66) ALKINSRIGF1REGFRMET
SCHEMBL26906927 0.78 EGFR (0.66) ALKINSRIGF1REGFRMET
SCHEMBL26906557 0.77 EGFR (0.53) ALKINSRIGF1REGFRMET
SCHEMBL30860292 0.77 EGFR (0.49) ALKINSRIGF1REGFRMET
SCHEMBL26906487 0.76 EGFR (0.65) ALKINSRIGF1REGFRMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US claimed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP claimed
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME THERAPEX CO., LTD. (KR) 2024-07-11 — — US disclosed
EP-4286376-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME Therapex Co., Ltd. (KR) 2023-12-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228458-A1 PYRIMIDINE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING SAME EGFR, ERBB2, ERBB3 ALK 120/4885INSR 607/4885IGF1R 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback